Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic …

F Ge, Z Huo, X Cai, Q Hu, W Chen, G Lin… - JAMA network …, 2022 - jamanetwork.com
Importance A considerable number of clinical trials of neoadjuvant immunotherapy for
patients with resectable esophageal cancer are emerging. However, systematic evaluations …

Surgical management of gastric cancer: a review

GZ Li, GM Doherty, J Wang - JAMA surgery, 2022 - jamanetwork.com
Importance Surgery plays a critical role in the management of all stages of gastric cancer.
Observations For patients with early gastric cancer and low risk of lymph node metastasis …

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

ZX Wang, C Cui, J Yao, Y Zhang, M Li, J Feng, S Yang… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT …

Z Lu, J Wang, Y Shu, L Liu, L Kong, L Yang, B Wang… - Bmj, 2022 - bmj.com
Objective To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin
plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally …

Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer

T Kojima, MA Shah, K Muro, E Francois… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open …

[HTML][HTML] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell …

J Liu, Y Yang, Z Liu, X Fu, X Cai, H Li… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Camrelizumab and chemotherapy demonstrated durable antitumor activity with
a manageable safety profile as first-line treatment in patients with advanced esophageal …

[HTML][HTML] Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

C Li, S Zhao, Y Zheng, Y Han, X Chen, Z Cheng… - European journal of …, 2021 - Elsevier
Background To investigate the safety and activity of preoperative pembrolizumab combined
with chemoradiotherapy for resectable oesophageal squamous cell carcinoma …

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges

M Garcia-Pardo, M Makarem, JJN Li, D Kelly… - British Journal of …, 2022 - nature.com
In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Interventional gastroenterology in oncology

V Wadhwa, N Patel, D Grover, FS Ali… - CA: A Cancer Journal …, 2023 - Wiley Online Library
Cancer is one of the foremost health problems worldwide and is among the leading causes
of death in the United States. Gastrointestinal tract cancers account for almost one third of …

[HTML][HTML] Clinical practice guideline for endoscopic resection of early gastrointestinal cancer

찬혁박, 동훈양, 정욱김, 지현김… - The Korean Journal …, 2020 - synapse.koreamed.org
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic
resection is now a standard treatment for early gastrointestinal cancers without regional …